Well, the vaccine being tested during that trial, Typbar TCV, the world’s first conjugate typhoid vaccine, has been approved by the World Health Organization (WHO).

In 2016 alone, there were an estimated 130,000 deaths from typhoid. As the potential for antimicrobial resistance increases, so too does the incidence of multi-drug resistant typhoid. This vaccine gives hope to those working to combat this trend. Typbar TCV is also the first vaccine that can be safely administered to infants as young as 6 months of age.

The WHO announced that the vaccine, developed by Bharat Biotech, received pre-qualification last week and many organizations are already lining up to procure it. GAVI, the Vaccine Alliance recently approved $85 million to make Typbar TCV available in GAVI-supported countries. Typbar TCV will be available to GAVI at a price of $1.50 per dose. Dr. Seth Berkley, CEO of GAVI, announced that first introductions are expected to take place beginning in 2019.